Patents by Inventor Joseph A. Fraietta

Joseph A. Fraietta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CAR T CELL THERAPIES WITH ENHANCED EFFICACY
    Publication number: 20240076372
    Abstract: The invention provides methods for manufacturing optimized CAR T cell therapies and uses thereof. Specifically, the invention provides parameters that can be measured, e.g., evaluated, to manufacture CAR T cell therapies with optimized properties. The invention further provides methods of use in connection with said optimized CAR T cells.
    Type: Application
    Filed: March 6, 2023
    Publication date: March 7, 2024
    Inventors: Christopher Loren Nobles, Frederic Dixon Bushman, Joseph A. Fraietta, Simon Lacey, Jan J. Melenhorst, Carl H. June
  • CAR T CELL THERAPIES WITH ENHANCED EFFICACY
    Publication number: 20230139800
    Abstract: The invention provides compositions and methods improved CAR T cell therapies. Specifically, the invention provides cells with reduced Tet, e.g., Tet2 function or expression, and methods of use therefore. The invention further provides Tet2 inhibitors and methods of use therefore in connection with CAR T cells.
    Type: Application
    Filed: September 20, 2022
    Publication date: May 4, 2023
    Inventors: Gregory Motz, Frederic Dixon Bushman, Joseph A. Fraietta, Carl H. June, Jan J. Melenhorst, Christopher Loren Nobles, Regina M. Young
  • BIOMARKERS FOR EVALUATING CAR-T CELLS TO PREDICT CLINICAL OUTCOME
    Publication number: 20210396739
    Abstract: The invention provides biomarkers, e.g, cancer biomarkers, and methods of using said biomarkers. Specifically, the invention provides biomarkers for use, e.g., in evaluating CAR-T cell therapies and predicting clinical outcome.
    Type: Application
    Filed: May 1, 2019
    Publication date: December 23, 2021
    Inventors: Iulian Pruteanu-Malinici, Jennifer Brogdon, Elena Orlando, Jan J. Melenhorst, Joseph A. Fraietta
  • CAR T CELL THERAPIES WITH ENHANCED EFFICACY
    Publication number: 20210047405
    Abstract: The invention provides methods for manufacturing optimized CAR T cell therapies and uses thereof. Specifically, the invention provides parameters that can be measured, e.g., evaluated, to manufacture CAR T cell therapies with optimized properties. The invention further provides methods of use in connection with said optimized CART cells.
    Type: Application
    Filed: April 26, 2019
    Publication date: February 18, 2021
    Inventors: Christopher Loren Nobles, Frederic Dixon Bushman, Joseph A. Fraietta, Simon Lacey, Jan J. Melenhorst, Carl H. June
  • BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND USES THEREOF
    Publication number: 20200371091
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to a method of administering a BCMA-targeting chimeric antigen receptor (CAR) therapy and an additional therapeutic agent.
    Type: Application
    Filed: November 30, 2018
    Publication date: November 26, 2020
    Inventors: Iulian Pruteanu-Malinici, Keith Mansfield, Boris Engels, Jan J. Melenhorst, Adam David Cohen, Edward A. Stadtmauer, Alfred Garfall, Michael C. Milone, Joseph A. Fraietta
  • METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS
    Publication number: 20200370012
    Abstract: The disclosure provides methods of making CAR-expressing immune effector cells (e.g., T cells, or NK cells), and compositions and reaction mixtures comprising the same. The disclosure further provides methods of using said CAR-expressing immune effector cells.
    Type: Application
    Filed: October 25, 2018
    Publication date: November 26, 2020
    Inventors: Joseph A. Fraietta, Jan J. Melenhorst, Elena Orlando, Roderick O'Connor, Carl H. June
  • BIOMARKERS AND CAR T CELL THERAPIES WITH ENHANCED EFFICACY
    Publication number: 20200087376
    Abstract: The invention provides compositions and methods improved CAR T cell therapies. Specifically, the invention provides cells with altered expression and/or function of one or more genes, e.g., associated with Tet2, and methods of use therefore. The invention further provides inhibitors of the one or more genes and methods of use therefore in connection with CAR T cells.
    Type: Application
    Filed: March 22, 2018
    Publication date: March 19, 2020
    Inventors: Joseph A. Fraietta, Jan J. Melenhorst
  • TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20190388471
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
    Type: Application
    Filed: June 7, 2019
    Publication date: December 26, 2019
    Applicants: Novartis AG, The Trustees of the University of Pennsylvania, The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, David L. Porter, Marcela Maus, Mariusz Wasik, Saar Gill, Joseph A. Fraietta, Marco Ruella, John Byrd, Jason Dubovsky, Amy Johnson, Natarajan Muthusamy, Saad Kenderian, Joan Mannick, David Jonathan Glass, Leon Murphy, Jennifer Brogdon, William Raj Sellers
  • Treatment of cancer using anti-CD19 Chimeric Antigen Receptor
    Patent number: 10357514
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: July 23, 2019
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Carl H. June, David L. Porter, Marcela Maus, Mariusz Wasik, Saar Gill, Joseph Fraietta, Marco Ruella, John Byrd, Jason Dubovsky, Amy Johnson, Natarajan Muthusamy, Saad Kenderian, Joan Mannick, David Glass, Leon Murphy, Jennifer Brogdon, William Raj Sellers
  • CAR T CELL THERAPIES WITH ENHANCED EFFICACY
    Publication number: 20180258149
    Abstract: The invention provides compositions and methods improved CAR T cell therapies. Specifically, the invention provides cells with reduced Tet, e.g., Tet2 function or expression, and methods of use therefore. The invention further provides Tet2 inhibitors and methods of use therefore in connection with CAR T cells.
    Type: Application
    Filed: September 16, 2016
    Publication date: September 13, 2018
    Applicants: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Gregory Motz, Frederic Dixon Bushman, Joseph A. Fraietta, Carl H. June, Jan J. Melenhorst, Christopher Loren Nobles, Regina M. Young
  • COMBINATION OF CHIMERIC ANTIGEN RECEPTOR THERAPY AND AMINO PYRIMIDINE DERIVATIVES
    Publication number: 20180140602
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a BTK inhibitor, e.g., an amino pyrimidine derivative described herein. The invention also provides kits and compositions described herein.
    Type: Application
    Filed: April 7, 2016
    Publication date: May 24, 2018
    Inventors: Daniela Angst, John Byrd, Jason Dubovsky, Joseph A. Fraietta, Francois Gessier, Saar Gill, Amy Johnson, Carl H. June, Marcela Maus, Natarajan Muthusamy, David L. Porter, Marco Ruella, Anna Vulpetti, Mariusz Wasik
  • TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20150283178
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
    Type: Application
    Filed: April 7, 2015
    Publication date: October 8, 2015
    Inventors: Carl H. June, David L. Porter, Marcela Maus, Mariusz Wasik, Saar Gill, Joseph Fraietta, Marco Ruella, John Byrd, Jason Dubovsky, Amy Johnson, Natarajan Muthusamy, Saad Kenderian, Joan Mannick, David Glass, Leon Murphy, Jennifer Brogdon, William Raj Sellers